In an interview with PharmaShots, Mark Gurney, CEO at Tetra Therapeutics shared his views on the results of the P-II exploratory study of BPN14770 in adult patients with Fragile X […]readmore
Tags : Tetra Therapeutics
Shots: The P-II study is a two-way crossover study assessing BPN14770 (25mg, bid) vs PBO in 30 adult male patients aged 18-45yrs. with FXS due to >200 CGG repeats in […]readmore
Shots: Shionogi to acquire Tetra for a total value of up to $500M which includes regulatory and commercial milestones, based on certain achievements. Following the acquisition, Shionogi will get global […]readmore
1. I-Mab to Initiate the Development of TJM2 for Treating Cytokine Release Syndrome Associated with COVID-19 Published: Mar 13, 2020 | Tags: I-Mab, Initiate, Development, TJM2, Treating, Cytokine Release Syndrome, COVID-19 […]readmore
Shots: The companies collaborate to develop and commercialize BPN14770 for AD, Fragile X syndrome and other indications marked by cognitive and memory deficits. Shionogi has increased its equity investment in […]readmore